Compare Spyre Therapeutics Inc. Common Stock (SYRE) vs Tidewater Inc (TDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Spyre Therapeutics Inc. Common Stock vs Tidewater Inc — how do they compare? Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B), while Tidewater Inc trades at $83.01 (market cap $4.33B). The key difference: Spyre Therapeutics Inc. Common Stock is the larger of the two by market cap, and Tidewater Inc is more actively traded (553,078 versus 1,441,031). Which is the better fit depends on your goals — on Pluang, investors hold Spyre Therapeutics Inc. Common Stock for 0 Days and Tidewater Inc for 27 Days on average.
| SYRE | TDW | |
|---|---|---|
Market Cap | $7.52B | $4.33B |
Volume | 1,441,031 | 553,078 |
Sector | Health | Energy |
52-Week High | $108.92 | $100.61 |
52-Week Low | $22.18 | $47.29 |
Typical Hold Time | 0 Days | 27 Days |
Enterprise Value | $6.52B | $4.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Tidewater (TDW) trades at $86.97, up 0.6% on the day, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $105.50. The company reported strong 2025 results with $1.35B revenue and $334.66M net income, though recent quarterly earnings have missed expectations. Positive developments include the completion of the Wilson Sons Ultratug acquisition in August 2026 and a significant $503.2M investment from BlackRock.
The stock offers potential upside to the price target, driven by operational strength and strategic acquisitions. Key risks include earnings volatility, competitive pressures in the energy sector, and exposure to geopolitical tensions affecting day rates. Investor sentiment is mixed, with 30.77% of analysts rating it a buy amid recent insider selling and institutional accumulation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →About Tidewater Inc
Tidewater is the leading global provider of offshore support vessels (OSVs) to the energy industry. With the world's largest fleet of platform supply vessels (PSVs) and anchor handling tugs (AHTS), it provides critical logistics and marine support for offshore oil, gas, and renewable energy projects. Following a period of massive strategic consolidation, Tidewater is now focused on maximizing day rates and free cash flow in a supply-constrained market, positioning itself as a primary beneficiary of the multi-year offshore upcycle.
Read more on TDW →
